<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612713</url>
  </required_header>
  <id_info>
    <org_study_id>2000020857</org_study_id>
    <secondary_id>1R21DA045969-01</secondary_id>
    <secondary_id>1K01DA039299-01A1</secondary_id>
    <nct_id>NCT03612713</nct_id>
  </id_info>
  <brief_title>Influence of Medication on Functional Connectivity</brief_title>
  <official_title>Influence of Medication on Functional Connectivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effects of acute low-dose opioid administration on functional
      neuroimaging measures in healthy individuals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the effects of acute low-dose opioid administration on functional
      neuroimaging measures in healthy individuals (N=40, 20 male, 20 female). The objective of
      this research is to develop an understanding of factors that may influence individual
      variability on resting state functional connectivity in response to low-dose opioid
      administration with the longer term aim of understanding addictions vulnerability.
      Specifically, the proposed pilot research will explore the effects of single dose of
      oxycodone (15mg) on resting state functional connectivity and other common neuroimaging
      measures (e.g., diffusion MRI, structural MRI).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in functional connectivity following oxycodone administration</measure>
    <time_frame>Change in functional connectivity from initial fMRI scan to follow-up MRI scan, up to 4 weeks.</time_frame>
    <description>Functional connectivity is measured by functional magnetic resonance imagery (fMRI). Change in functional connectivity between placebo and oxycodone fMRI scans will be assessed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prescription Drug Abuse (Not Dependent)</condition>
  <arm_group>
    <arm_group_label>Oxycodone Medication First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one hour before fMRI scan participants will be given a single dose placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone Medication First</intervention_name>
    <description>Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.</description>
    <arm_group_label>Oxycodone Medication First</arm_group_label>
    <other_name>Oxycodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo First</intervention_name>
    <description>Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.</description>
    <arm_group_label>Placebo First</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. males or females, ages 18-30

          2. for women of a child-bearing age, acceptable birth control methods or a negative
             pregnancy test prior to MRI scanning

          3. ability to provide written, informed consent

          4. eligibility and willingness to participate in fMRI scanning and to receive oxycodone

          5. normal weight, as indicated by a body mass index (BMI) between 18.5 to 25

        Exclusion Criteria:

          1. current DSM-5 Axis I disorder

          2. any psychotropic medication or medication known to interfere with metabolism of
             opioids

          3. medical contraindication to participate in study activities (acute low-dose opioid
             admin) as determined by study physician

          4. known family history (first-degree relative) of opioid-use disorder or alcohol-use
             disorder

          5. not eligible for MRI scanning

          6. positive drug screen

          7. recent (past 6 months) medical or non-medical opioid-use

          8. current or previous chronic pain disorder

          9. significant lifetime use of prescription opioids (&gt;7 days of consecutive medical use
             or nonmedical use on more than 5 occasions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Yip, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Magnetic Resonance Research Center at The Anlyan Center Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

